EG24515A - C-aryl glucoside SGLT2 inhibitors and method - Google Patents

C-aryl glucoside SGLT2 inhibitors and method

Info

Publication number
EG24515A
EG24515A EG20001279A EG20001279A EG24515A EG 24515 A EG24515 A EG 24515A EG 20001279 A EG20001279 A EG 20001279A EG 20001279 A EG20001279 A EG 20001279A EG 24515 A EG24515 A EG 24515A
Authority
EG
Egypt
Prior art keywords
sglt2 inhibitors
aryl glucoside
glucoside sglt2
aryl
inhibitors
Prior art date
Application number
EG20001279A
Other languages
English (en)
Inventor
Bruce Ellsworth
Philip M Sher
William N Washburn
Gang Wu
Wei Meng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26855382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24515(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24515A publication Critical patent/EG24515A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EG20001279A 1999-10-12 2000-10-09 C-aryl glucoside SGLT2 inhibitors and method EG24515A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15877399P 1999-10-12 1999-10-12
US19461500P 2000-04-05 2000-04-05

Publications (1)

Publication Number Publication Date
EG24515A true EG24515A (en) 2009-08-19

Family

ID=26855382

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20001279A EG24515A (en) 1999-10-12 2000-10-09 C-aryl glucoside SGLT2 inhibitors and method

Country Status (32)

Country Link
US (1) US6414126B1 (pl)
EP (1) EP1224195B1 (pl)
JP (1) JP4365554B2 (pl)
KR (1) KR100728085B1 (pl)
CN (1) CN1284793C (pl)
AR (1) AR026024A1 (pl)
AT (1) ATE295848T1 (pl)
AU (1) AU781009B2 (pl)
BR (2) BR0014722A (pl)
CA (1) CA2388818C (pl)
CO (1) CO5251414A1 (pl)
CZ (1) CZ304522B6 (pl)
DE (1) DE60020259T2 (pl)
EG (1) EG24515A (pl)
ES (1) ES2240179T3 (pl)
HK (1) HK1044541B (pl)
HU (2) HU229446B1 (pl)
IL (2) IL148806A0 (pl)
IN (1) IN2007MU00019A (pl)
MX (1) MX237254B (pl)
MY (1) MY125405A (pl)
NO (2) NO323698B1 (pl)
NZ (1) NZ518029A (pl)
PE (1) PE20011000A1 (pl)
PH (1) PH12000002657B1 (pl)
PL (1) PL204358B1 (pl)
PT (1) PT1224195E (pl)
RU (1) RU2262507C2 (pl)
TR (1) TR200200986T2 (pl)
TW (1) TWI254714B (pl)
UY (1) UY26391A1 (pl)
WO (1) WO2001027128A1 (pl)

Families Citing this family (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PT1616561E (pt) * 1999-12-28 2008-07-09 Ajinomoto Kk Preparação antidiabética para administração oral
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
NZ537490A (en) * 2000-10-30 2006-11-30 Ortho Mcneil Pharm Inc Treatment of diabetes and syndrome X using a sulfamate derivate such as topiramate and metformin
JP2004525109A (ja) * 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
JPWO2003011880A1 (ja) * 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20040043066A1 (en) * 2001-10-29 2004-03-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
WO2003043624A1 (en) * 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2002351752A1 (en) * 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20060052457A1 (en) * 2002-03-11 2006-03-09 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20050215489A1 (en) * 2002-03-14 2005-09-29 Bayer Pharmaceuticals Corporation Methods of treating diabetes using pde 11a inhibitors
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
EP1500403A4 (en) * 2002-04-26 2008-09-17 Ajinomoto Kk MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
CA2500873C (en) * 2002-10-04 2012-01-17 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2003299966A1 (en) 2003-01-03 2004-08-10 Bristol-Myers Squibb Company Methods of producing c-aryl glucoside sglt2 inhibitors
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
CN1802366B (zh) * 2003-03-14 2010-12-22 安斯泰来制药有限公司 C-糖苷衍生物及其盐
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2004233693B2 (en) * 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
US7772272B2 (en) * 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
RS20060320A (sr) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
TW200524951A (en) 2003-08-01 2005-08-01 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
AU2004261660A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
MXPA06001274A (es) 2003-08-01 2006-04-11 Tanabe Seiyaku Co Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EP1680131A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDOLE-O-GLUCOSIDES
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005038013A1 (en) * 2003-10-07 2005-04-28 Isis Pharmaceuticals, Inc. Artisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP1689757B1 (en) 2003-11-12 2014-08-27 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1581246B1 (en) * 2003-12-17 2013-01-16 Amylin Pharmaceuticals, LLC Compositions for the treatment and prevention of nephropathy
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
WO2005085237A1 (ja) * 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
RU2387663C2 (ru) * 2004-03-04 2010-04-27 Киссеи Фармасьютикал Ко., Лтд. Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
EP2360165A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2560005A1 (en) * 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
TW200602335A (en) * 2004-03-31 2006-01-16 Kissei Pharmaceutical Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
JPWO2005095372A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US20070293690A1 (en) * 2004-07-08 2007-12-20 Hiroshi Tomiyama Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
EP1782828B1 (en) * 2004-07-21 2016-06-29 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) * 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP5046370B2 (ja) * 2004-09-29 2012-10-10 キッセイ薬品工業株式会社 １−（β−Ｄ−グリコピラノシル）−３−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006064033A2 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
ZA200706022B (en) * 2005-01-28 2008-11-26 Chugai Pharmaceutical Co Ltd Spiroketal derivatives and use thereof as diabetic medicine
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP4496174B2 (ja) * 2005-01-31 2010-07-07 田辺三菱製薬株式会社 医薬組成物
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
WO2006089872A1 (en) * 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
WO2006099245A1 (en) * 2005-03-11 2006-09-21 Elixir Pharmaceuticals, Inc. Sirt inhibitors that bind to nad
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) * 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
ES2346347T3 (es) * 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
ATE484499T1 (de) * 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
CN101238112A (zh) 2005-09-08 2008-08-06 贝林格尔·英格海姆国际有限公司 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AU2007216452A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
TW200812995A (en) 2006-05-19 2008-03-16 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound
US7803778B2 (en) * 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2655937A1 (en) * 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7858587B2 (en) * 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN101522699A (zh) 2006-10-13 2009-09-02 中外制药株式会社 硫葡萄糖螺缩酮衍生物、及其作为糖尿病治疗药的应用
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5298025B2 (ja) * 2006-12-04 2013-09-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体
CN101657471B (zh) 2006-12-06 2013-07-03 史密丝克莱恩比彻姆公司 二环化合物及其作为抗糖尿病药的用途
MX2009006444A (es) 2006-12-21 2009-06-26 Astellas Pharma Inc Metodo para producir derivado de c-glucosido e intermediario sintetico del mismo.
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
JP2010519273A (ja) * 2007-02-21 2010-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN104803957A (zh) * 2007-04-02 2015-07-29 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
JP2010528023A (ja) * 2007-05-18 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤の結晶構造およびその製造方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
DE602008006081D1 (de) 2007-07-05 2011-05-19 Centre Nat Rech Scient Neue phosphorhaltige heterocyclische verbindungen, zuckeranaloga und zusammensetzungen mit antikrebswirkung, die diese enthalten
CN101343296B (zh) * 2007-07-10 2013-04-10 莱西肯医药有限公司 钠-葡萄糖协同转运蛋白2的抑制剂及其用法
ES2375800T3 (es) * 2007-07-26 2012-03-06 Lexicon Pharmaceuticals, Inc. Métodos y compuestos útiles para la preparación de inhibidores de cotransportador 2 de sódio-glucosa.
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2009026537A1 (en) 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use
CN101801371B (zh) 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
US8450286B2 (en) 2008-03-18 2013-05-28 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof
FR2929615B1 (fr) * 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
BRPI0913129A2 (pt) 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PT2324002T (pt) 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
MX2011002166A (es) * 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
RU2411936C2 (ru) * 2009-01-11 2011-02-20 Институт физиологии Коми научного центра Уральского отделения Российской академии наук. Государственное учреждение Применение 2-морфолино-5-фенил-6н-1,3,4-тиадизин, гидробромида в качестве средства, обладающего гиполипидемическим и гипергликемическим эффектом
MY161472A (en) 2009-02-13 2017-04-14 Boehringer Ingelheim Int Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
MX345494B (es) * 2009-02-13 2017-02-02 Boehringer Ingelheim Int Gmbh * Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
WO2010104830A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2435033A1 (en) * 2009-05-27 2012-04-04 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (ko) 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
HUE029381T2 (en) 2009-09-30 2017-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
SG10201500258WA (en) 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
KR20120087950A (ko) 2009-10-20 2012-08-07 노파르티스 아게 글리코시드 유도체 및 그의 용도
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
CN104825417A (zh) 2009-11-13 2015-08-12 阿斯利康(瑞典)有限公司 立即释放片剂
WO2011070592A2 (en) * 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
IL295438B2 (en) 2011-01-05 2026-05-01 Lexicon Pharmaceuticals Inc Compositions containing and methods for using inhibitors of sodium-glucose cotransporters 1 and 2
EP2670397B1 (en) 2011-02-01 2020-05-13 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012109996A1 (zh) 2011-02-18 2012-08-23 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102675378A (zh) * 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
WO2012125622A1 (en) 2011-03-14 2012-09-20 Bristol-Myers Squibb Company Substituted adipic acid amides and uses thereof
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
CN103619862A (zh) 2011-04-14 2014-03-05 诺瓦提斯公司 糖苷衍生物及其用途
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
JP5876570B2 (ja) * 2011-06-01 2016-03-02 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体
EA201301354A1 (ru) 2011-06-03 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
WO2012172566A2 (en) * 2011-06-13 2012-12-20 Panacea Biotec Ltd. Novel sglt inhibitors
CN102827122B (zh) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 糖苷衍生物
WO2013000275A1 (zh) * 2011-06-25 2013-01-03 山东轩竹医药科技有限公司 C-糖苷衍生物
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8710049B2 (en) 2011-07-18 2014-04-29 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
EP2755722B1 (en) * 2011-09-13 2017-05-24 Panacea Biotec Ltd. Novel sglt inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2013152476A1 (en) 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
CN103450214B (zh) * 2012-05-29 2016-04-06 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
JP6198013B2 (ja) * 2012-08-30 2017-09-20 大正製薬株式会社 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
PT3466431T (pt) 2013-03-14 2024-01-26 Msd Int Gmbh Formas cristalinas e métodos para preparação de inibidores de sglt2
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN104059042B (zh) * 2013-03-22 2017-02-08 正大天晴药业集团股份有限公司 C-三芳基葡萄糖苷类sglt-2抑制剂
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
KR102309654B1 (ko) 2013-04-18 2021-10-08 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
CN105518014B (zh) * 2013-09-09 2018-03-23 上海研健新药研发有限公司 C‑芳基葡糖苷衍生物、其制备方法及其在医药上的应用
US9394329B2 (en) 2013-09-27 2016-07-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
ES2969764T3 (es) 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
WO2015101916A1 (en) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
EP2891654B1 (en) 2014-01-03 2016-06-22 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
CN115282284A (zh) * 2014-01-23 2022-11-04 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
IN2014CH01141A (pl) * 2014-03-06 2015-09-11 Msn Lab Private Ltd
ES2811261T3 (es) 2014-04-01 2021-03-11 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
TW201623321A (zh) 2014-05-13 2016-07-01 韓美藥品股份有限公司 雙環衍生物及包含其之藥學組成物
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN105085494B (zh) * 2014-05-22 2019-07-02 中国医学科学院药物研究所 钠糖共转运体2抑制剂、其制法和其药物组合物与用途
JP2017528499A (ja) 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
CN104327027B (zh) * 2014-10-14 2017-04-05 中国药科大学 一类新型c‑芳基葡萄糖苷sglt2抑制剂
EP3256482B1 (en) * 2015-02-09 2019-11-27 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2016161995A1 (en) 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
MX389367B (es) 2015-08-27 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EP3362055B1 (en) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
WO2017099496A1 (ko) 2015-12-11 2017-06-15 동아에스티 주식회사 다파글리플로진의 신규 용매화물 및 이의 제조방법
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) * 2015-12-28 2016-06-22 南昌大学 一种抗糖尿病化合物及其制备方法和用途
UA122083C2 (uk) * 2016-01-04 2020-09-10 Че Іль Фармасьютікал Ко., Лтд. C-глікозидні похідні, які містять конденсоване фенільне кільце, або їхні фармацевтично прийнятні солі, спосіб одержання таких і фармацевтична композиція, що містить такі
WO2017141202A1 (en) 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
US9834533B2 (en) * 2016-02-19 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017221211A1 (en) * 2016-06-24 2017-12-28 Biocon Limited Process for the preparation of dapagliflozin and its solvate thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CA3039745A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
KR20200022257A (ko) * 2018-08-22 2020-03-03 동아에스티 주식회사 Sglt-2 억제제인 다파글리플로진 전구체의 제조방법
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
SG11202102440SA (en) 2018-10-29 2021-04-29 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020151621A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及医药用途
CN111471031B (zh) * 2019-01-24 2023-05-16 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
CN111471032B (zh) * 2019-01-24 2023-08-01 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
CN111471040B (zh) * 2019-01-24 2023-06-02 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
CN111840271B (zh) * 2019-04-25 2024-05-14 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物新用途
JOP20200098A1 (ar) 2019-08-30 2021-02-28 Astrazeneca Ab طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
CN114727624A (zh) 2019-11-28 2022-07-08 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂在非人哺乳动物的停奶中的用途
PE20231066A1 (es) 2020-02-07 2023-07-17 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
JP2021127332A (ja) * 2020-02-17 2021-09-02 株式会社トクヤマ ５−ブロモ−２−アルキル安息香酸の製造方法
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN115209894B (zh) 2020-03-06 2025-05-02 弗特克斯药品有限公司 治疗apol-1依赖性局灶节段性肾小球硬化的方法
WO2021214023A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP4143183B1 (en) 2020-04-29 2025-10-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20230165856A1 (en) 2020-04-29 2023-06-01 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
CN115867538A (zh) 2020-06-05 2023-03-28 新梅斯托克公司 高纯的无定形达格列净的制备
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
PT4188389T (pt) 2020-07-27 2025-10-07 Astrazeneca Ab Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
EP4249479A4 (en) * 2020-11-19 2024-12-18 Beijing Increase Innovative Drug Co., Ltd. GLUCOSIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION
KR20220091233A (ko) 2020-12-23 2022-06-30 (주)국전약품 다파글리플로진 전구약물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
MX2024001185A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades renales en mamiferos no humanos.
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4531810A1 (en) 2022-05-25 2025-04-09 Boehringer Ingelheim Vetmedica GmbH Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024033288A1 (en) * 2022-08-12 2024-02-15 Société des Produits Nestlé S.A. Salicin derivatives as inhibitors of sglt2
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
KR20260019532A (ko) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
WO2025224069A1 (en) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
CN1149082C (zh) 1995-06-29 2004-05-12 得克萨斯生物技术公司 二价和三价小分子选择蛋白抑制剂
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
TW406086B (en) 1996-12-26 2000-09-21 Tanabe Seiyaku Co Propiophenone derivatives and process for preparing the same
AU6024998A (en) * 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
UA71994C2 (en) * 1999-08-31 2005-01-17 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof

Also Published As

Publication number Publication date
DE60020259T2 (de) 2006-01-19
PE20011000A1 (es) 2001-11-25
CA2388818C (en) 2012-07-03
NZ518029A (en) 2004-08-27
HU230727B1 (hu) 2017-12-28
MY125405A (en) 2006-07-31
PH12000002657B1 (en) 2006-02-21
HK1044541B (en) 2005-11-11
EP1224195A1 (en) 2002-07-24
HUP0300393A2 (hu) 2003-06-28
PL204358B1 (pl) 2010-01-29
US6414126B1 (en) 2002-07-02
DE60020259D1 (de) 2005-06-23
RU2002109477A (ru) 2004-01-20
CA2388818A1 (en) 2001-04-19
IN2007MU00019A (pl) 2007-08-03
ES2240179T3 (es) 2005-10-16
NO20070149L (no) 2002-06-10
IL148806A0 (en) 2002-09-12
UY26391A1 (es) 2001-05-31
KR20020063876A (ko) 2002-08-05
CO5251414A1 (es) 2003-02-28
KR100728085B1 (ko) 2007-06-14
WO2001027128A1 (en) 2001-04-19
NO20021721L (no) 2002-06-10
CZ20021285A3 (cs) 2003-02-12
AR026024A1 (es) 2002-12-26
AU781009B2 (en) 2005-04-28
PL355018A1 (pl) 2004-03-22
HUP0300393A3 (en) 2003-09-29
CZ304522B6 (cs) 2014-06-18
EP1224195B1 (en) 2005-05-18
ATE295848T1 (de) 2005-06-15
AU7848300A (en) 2001-04-23
NO332798B1 (no) 2013-01-14
CN1284793C (zh) 2006-11-15
HU229446B1 (en) 2013-12-30
TWI254714B (en) 2006-05-11
RU2262507C2 (ru) 2005-10-20
HK1044541A1 (en) 2002-10-25
BRPI0014722B8 (pt) 2021-05-25
MXPA02003625A (es) 2002-10-23
BR0014722A (pt) 2003-02-25
TR200200986T2 (tr) 2002-07-22
JP4365554B2 (ja) 2009-11-18
MX237254B (es) 2006-05-26
NO20021721D0 (no) 2002-04-11
JP2003511458A (ja) 2003-03-25
IL148806A (en) 2010-06-16
BRPI0014722B1 (pt) 2019-09-24
PT1224195E (pt) 2005-07-29
CN1407990A (zh) 2003-04-02
NO323698B1 (no) 2007-06-25

Similar Documents

Publication Publication Date Title
PH12000002657B1 (en) C-aryl glucoside SGLT2 inhibitors
HRP20041084A2 (en) C-aryl glucoside sglt2 inhibitors and method
HUP0301513A3 (en) O-aryl glucoside sglt2 inhibitors and method
AU3517899A (en) Interception system and method
EP1287449A4 (en) APPLICATION CACHE SYSTEM AND METHOD
GB0028079D0 (en) System and method
AU2002363055A8 (en) System and method for interative advertising
AU2002356501A1 (en) Rotary ejector enhanced pulsed detonation system and method
GB0104627D0 (en) Method and device for crushing glass bodies
IL140019A0 (en) Communication system and communication method
HUP0300831A3 (en) Method and composition for masking mineral taste
GB0019500D0 (en) System and method
ZA200202604B (en) C-aryl glucoside SGLT2 inhibitors.
PL353770A1 (pl) Gen Streptomyces avermitilis decydujący o stosunkuGen Streptomyces avermitilis decydujący o stosunku awermektyn B1:B2 awermektyn B1:B2
AUPP807799A0 (en) Polynucleotide and method
AU4797900A (en) Brachytherapy device and method
PL353874A1 (pl) Gen Streptomyces avermitilis decydujący o stosunkuGen Streptomyces avermitilis decydujący o stosunku awermektyn B1:B2 awermektyn B1:B2
DK1224195T3 (da) C-Aryl-glucosid-SGLT2-inhibitorer
AU1719700A (en) Selective inhibitors of mmp-12
AU2002326840A1 (en) O-pyrazole glucoside sglt2 inhibitors and method of use
AU1896201A (en) Interception method of earth-ray
GB0025993D0 (en) Betting system and method
PL326261A1 (en) Method of manufacturing of glycosides of n-alkiloxycarbonyl derivatives of l-acosamine
AUPQ602900A0 (en) Menstrual cycle calculation method and system
AU5018101A (en) Microlicensing system and method